RCS - Aptamer Group PLC - Aptamer & Neuro-Bio to develop Alzheimer’s test

AptamerAnnouncement

14/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230614:nRSN6075Ca&default-theme=true

RNS Number : 6075C  Aptamer Group PLC  14 June 2023

14 June 2023

 

Aptamer Group plc

("Aptamer", or " the Group")

 

Aptamer Group and Neuro-Bio partner to develop an Alzheimer's disease
diagnostic test

 

-       Optimer binders have been successfully developed to a novel
Alzheimer's disease biomarker

-       Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio's
Science Day on Optimer technology and the development of binders to support
the diagnostic

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, and Neuro-Bio, an
Oxford-based biotechnology company with a therapeutic focus on
neurodegenerative disease, announce success in the development of Optimer
binders to enable a lateral flow test for the early diagnosis of Alzheimer's
disease.

Aptamer Group has successfully developed a panel of Optimer binders to a novel
Alzheimer's disease biomarker. The Optimer binders have been patented by
partners at Neuro-Bio, following the demonstration of performance in
specifically binding to the target biomarker and functionality in a nasal
mucous matrix. Further integration of the binders into a routine lateral flow
test will support the clinical and commercial development of rapid diagnostics
for Alzheimer's disease via simple nasal sampling, with the potential to
diagnose the disease as early as 10-20 years before symptoms emerge.

The novel Alzheimer's disease biomarker, a peptide 'T14'was discovered and is
currently being further validated by Neuro-Bio, led by the eminent
neuroscientist Baroness Susan Greenfield. Early detection of Alzheimer's
disease is critical to allow interventions that could prevent the onset of
devastating memory loss and confusion in these patients. Neuro-Bio is working
in parallel to develop a complementary therapy that could stabilise disease
progression in diagnosed patients, ideally at the presymptomatic stage.

Dr David Bunka, Chief Technical Officer of Aptamer Group, will take part in
Neuro-Bio's Science Day today at the Royal College of Physicians, discussing
the development of the Optimer binders in partnership with Neuro-Bio, and the
potential for diagnostic development.

Dr Rob Quinn, Interim Chief Executive Officer of Aptamer Group,
commented: "We are pleased to be able to support the team at Neuro-Bio with
the development of Optimer binders to enable their revolutionary diagnostic
for Alzheimer's disease. Optimer binders have proven performance in lateral
flow test formats and our success in delivering functional Optimer binders to
Neuro-Bio's biomarker facilitates further diagnostic development. With an
increasingly aging population and no current tests available for early-stage
diagnosis, the advancement of new biomarkers and diagnostics in this field
offers hope to the millions of patients and their loved ones worldwide."

Baroness Susan Greenfield, CEO of Neuro-Bio, commented: 'We're delighted to be
working with Aptamer Group on this potentially game-changing technology to
combat one of the biggest unmet medical needs of our time. It's a further
example of UK ingenuity and teamwork for highly innovative and disruptive
science.'

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Rob Quinn
 
   +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
 
+44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                    +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSRRFIVLIV